Summary

Continuous Glucose Monitoring Systems Market Research Report Information by Product (Sensors, And Transmitter and Receivers), By Application (Type 2, Type 1, Non-diabetic Patients), By End User (Hospitals & Clinics, Homecare Settings, And Others), by Region (North America, Europe, Asia-Pacific, and Rest of the World) Forecast till 2032

Market Overview
In 2023, the market for continuous glucose monitoring systems was estimated to be worth USD 8.8 billion. The Continuous Glucose Monitoring Systems Market is expected to increase from USD 10.0 billion in 2024 to USD 25.8 billion by 2032, with a compound yearly growth rate (CAGR) of 12.34% over the forecast period (2024-2032).
The rising prevalence of diabetes worldwide is a major factor driving the growth of the Continuous Glucose Monitoring Systems Market. Diabetes has reached epidemic proportions, with a dramatic increase in the number of affected people worldwide. According to the International Diabetes Federation (IDF), there were roughly 537 million diabetics globally in 2021, with the figure predicted to rise to 643 million by 2030. Similarly, the American Diabetes Association estimates that diabetes will afflict 38.4 million Americans, or 11.6% of the population, by 2021. Type 1 diabetes affects roughly 2.0 million Americans, including 304,000 children and adolescents. Diabetes is becoming more common as a result of sedentary lifestyles, poor dietary habits, and an aging population. As the diabetic population grows, the need for appropriate diabetes control options becomes increasingly urgent.

Market Segment insights
The Continuous Glucose Monitoring Systems Market Segmentation by Product covers sensors, transmitters, and receivers.
The market is segmented by application, which includes type 2 diabetes, type 1 diabetes, and non-diabetic individuals.
The market is segmented by end user, which includes hospitals and clinics, homecare settings, and others.

Regional insights
The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. North America the Continuous Glucose Monitoring Systems market held the biggest market share in 2023. This is due to the robust technology infrastructure and well-established regulatory framework, which are projected to boost the market.
Europe's Continuous Glucose Monitoring Systems market is the second largest, owing to the region's rising diabetes prevalence and advances in CGM technology. Furthermore, the France Continuous Glucose Monitoring Systems market was ascribed to hold the biggest market share, while the Rest of Europe Continuous Glucose Monitoring Systems market is predicted to be the fastest-growing market in the European area.
The Asia-Pacific Continuous Glucose Monitoring Systems market is predicted to develop significantly between 2023 and 2032. This is attributable to increased diabetes management awareness and the region's rising diabetes prevalence. Furthermore, China Continuous Glucose Monitoring Systems market is predicted to hold the greatest market share, followed by India. The Continuous Glucose Monitoring Systems market is predicted to be the fastest growing in the Asia-Pacific region.
The Rest of the World is divided into two regions: the Middle East and Africa, and Latin America. The Continuous Glucose Monitoring Systems market in the regions is expected to develop due to the rising prevalence of diabetes, as well as increased awareness of improved glucose monitoring systems, which supports market expansion.

Major Players
Dexcom, Inc (US), Menarini Diagnostics SRL (Italy), Sensonics (US), Medtrum Technologies Inc. (China), Nemaura Medical Inc. (US), Ultrahuman Healthcare Pvt Ltd (India), Medtronic (Ireland), One Drop (US), Abbott Laboratories, Inc. (US), and Sinocare (China) are among the key players in the Continuous Glucose Monitoring Systems Market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
3.5.1 PRIMARY RESEARCH DATA FLOW:
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
3.7.1 DATA FORECASTING TECHNIQUE
3.8 DATA MODELING
3.8.1 MICROECONOMIC FACTOR ANALYSIS:
3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 INCREASING PREVALENCE OF DIABETES
4.2.2 RISING AWARENESS AMONG INDIVIDUALS ABOUT THE BENEFITS OF CONTINUOUS GLUCOSE MONITORING AND PATIENT EDUCATION
4.2.3 INCREASING GERIATRIC POPULATION
4.3 RESTRAINTS
4.3.1 HIGH COST OF CONTINUOUS GLUCOSE MONITORING SYSTEMS
4.4 OPPORTUNITY
4.4.1 GROWING TECHNOLOGICAL ADVANCEMENTS AND INNOVATION
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION AND SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET
5.3.1 OVERVIEW
6 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY PRODUCT
6.1 OVERVIEW
6.2 SENSORS
6.3 TRANSMITTER & RECEIVERS
7 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 TYPE 2 DIABETES
7.3 TYPE 1 DIABETES
7.4 NON-DIABETIC PATIENTS
7.4.1 WEIGHT LOSS
7.4.2 DIET MANAGEMENT
7.4.3 HEALTH & WELLNESS
8 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS & CLINICS
8.3 HOMECARE SETTINGS
8.4 OTHERS
9 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY REGION
9.1 GLOBAL
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 FRANCE
9.3.3 UK
9.3.4 ITALY
9.3.5 SPAIN
9.3.6 REST OF EUROPE
9.4 ASIA-PACIFIC
9.4.1 CHINA
9.4.2 INDIA
9.4.3 JAPAN
9.4.4 SOUTH KOREA
9.4.5 AUSTRALIA
9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
9.5.1 MIDDLE EAST & AFRICA
9.5.2 LATIN AMERICA
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS, 2023
10.3 COMPETITOR DASHBOARD
10.4 PUBLIC PLAYERS STOCK SUMMARY
10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
10.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
10.6.2 AGREEMENT
10.6.3 PARTNERSHIP
10.6.4 COLLABORATION
11 COMPANY PROFILES
11.1 DEXCOM, INC
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 A. MENARINI DIAGNOSTICS SRL
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 KEY STRATEGIES
11.3 SENSEONICS
11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 KEY STRATEGIES
11.4 MEDTRUM TECHNOLOGIES INC.
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 KEY STRATEGIES
11.5 NEMAURA MEDICAL INC.
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS OFFERED
11.5.4 KEY DEVELOPMENTS
11.5.5 SWOT ANALYSIS
11.5.6 KEY STRATEGIES
11.6 ULTRAHUMAN HEALTHCARE PVT LTD
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS OFFERED
11.6.4 KEY DEVELOPMENTS
11.6.5 KEY STRATEGIES
11.7 MEDTRONIC
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCTS OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 SWOT ANALYSIS
11.7.6 KEY STRATEGIES
11.8 ONE DROP
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 SWOT ANALYSIS
11.8.6 KEY STRATEGIES
11.9 ABBOTT LABORATORIES, INC.
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCTS OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 SWOT ANALYSIS
11.9.6 KEY STRATEGIES
11.10 SINOCARE
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL OVERVIEW
11.10.3 PRODUCTS OFFERED
11.10.4 KEY DEVELOPMENTS
11.10.5 KEY STRATEGIES
11.11 NUTRISENSE
11.11.1 COMPANY OVERVIEW
11.11.2 FINANCIAL OVERVIEW
11.11.3 PRODUCTS OFFERED
11.11.4 KEY DEVELOPMENTS
11.11.5 KEY STRATEGIES
11.12 SUPERSAPIENS
11.12.1 COMPANY OVERVIEW
11.12.2 FINANCIAL OVERVIEW
11.12.3 PRODUCTS OFFERED
11.12.4 KEY DEVELOPMENTS
11.12.5 KEY STRATEGIES
11.13 SIGNOS INC.
11.13.1 COMPANY OVERVIEW
11.13.2 FINANCIAL OVERVIEW
11.13.3 PRODUCTS OFFERED
11.13.4 KEY DEVELOPMENTS
11.13.5 KEY STRATEGIES
11.14 LEVELS
11.14.1 COMPANY OVERVIEW
11.14.2 FINANCIAL OVERVIEW
11.14.3 PRODUCTS OFFERED
11.14.4 KEY DEVELOPMENTS
11.14.5 KEY STRATEGIES
11.15 VERI
11.15.1 COMPANY OVERVIEW
11.15.2 FINANCIAL OVERVIEW
11.15.3 PRODUCTS OFFERED
11.15.4 KEY DEVELOPMENTS
11.15.5 KEY STRATEGIES
11.16 LUMEN
11.16.1 COMPANY OVERVIEW
11.16.2 FINANCIAL OVERVIEW
11.16.3 PRODUCTS OFFERED
11.16.4 KEY DEVELOPMENTS
11.16.5 KEY STRATEGIES
11.17 JANUARY.AI
11.17.1 COMPANY OVERVIEW
11.17.2 FINANCIAL OVERVIEW
11.17.3 PRODUCTS OFFERED
11.17.4 KEY DEVELOPMENTS
11.17.5 KEY STRATEGIES
12 DATA CITATIONS